
PepGen Inc (PEPG) Stock Forecast & Price Target
PepGen Inc (PEPG) Analyst Ratings
Bulls say
PepGen is a clinical-stage biotechnology company with a promising platform for delivering oligonucleotide therapeutics to target tissues, including muscle and the central nervous system. Despite some early data concerns, the company has a strong pipeline with PGN-EDODM1 as the lead candidate. The upcoming FREEDOM-2 data in 2H26 will be a key catalyst for the stock, and while we remain positive on the potential of PGN-EDODM1, we have lowered our target to $5 due to increased safety concerns.
Bears say
PepGen is a clinical-stage biotechnology company that has developed a platform to improve the uptake and activity of oligonucleotide therapeutics. However, their PGN-EDODM1 drug has faced challenges, including a clinical hold and concerning splicing data in early trials. Additionally, the company may face delays or challenges in obtaining external funding. These factors, along with a recent increase in discount rate and a lowered valuation, contribute to the negative outlook on PepGen's stock.
This aggregate rating is based on analysts' research of PepGen Inc and is not a guaranteed prediction by Public.com or investment advice.
PepGen Inc (PEPG) Analyst Forecast & Price Prediction
Start investing in PepGen Inc (PEPG)
Order type
Buy in
Order amount
Est. shares
0 shares